Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biogen -- Ignore unavailable to you. Want to Upgrade?

To: Harold Engstrom who wrote (571)	1/22/1998 2:55:00 PM
From: Vector1	Respond to of 1686

From Eric Heckt's Jan 20 update regarding the pipeline: ---------- Product Pipeline Outlook More importantly, in 1998 several clinical trials should shed light on Biogen's pipeline potential. Biogen will report data on the use of Avonex in brain cancer. Biogen expects to have clinical data for CVT-124 for renal protection and LFA3-TIP for severe psoriasis. A phase II trial of CVT-124 for the intended market will begin in mid-1998 and data could be available in 1Q99. Data is being analyzed for a phase I trial of CD-40 ligand for ITP. Other indications for CD-40 ligand to be explored this year are Lupus and Factor VIII inhibition. The company intends to out-license Gelsolin, as the clinical data did not meet the internal threshold for advancement.